What does this video actually claim?
Mercedes G (@mercgroves) shows off dramatic weight loss results while promoting SHED, a telehealth platform that prescribes GLP-1 medications. She claims not to "recognize" her former self and uses hashtags suggesting she's achieved life-changing transformation through semaglutide or similar GLP-1 drugs.
The video follows a familiar before-and-after format popular on TikTok. While Mercedes doesn't make specific medical claims about dosing or timelines, her hashtags link her results directly to GLP-1 medications and position her as both a success story and brand partner for SHED.
Are these kinds of results actually possible?
Yes, but they're not guaranteed for everyone. The STEP 1 trial (Wilding et al., NEJM, 2021) showed that 2.4mg semaglutide led to average weight loss of 14.9% over 68 weeks. About one-third of participants lost 20% or more of their body weight.
The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) found even better results with tirzepatide. Participants on the 15mg dose lost an average of 22.5% of their body weight over 72 weeks. That's the kind of dramatic change Mercedes appears to show.
But here's what these studies also reveal: results vary wildly between individuals. Some people lost 30% or more, while others saw minimal changes. Mercedes's transformation, while impressive, represents the upper end of what's possible, not what everyone should expect.
What's missing from this success story?
Mercedes doesn't mention the less glamorous realities of GLP-1 treatment that clinical trials document extensively. The STEP 1 trial reported that 74.2% of semaglutide users experienced gastrointestinal side effects, including nausea, vomiting, and diarrhea.
She also doesn't discuss timeline or dosing. Most people start at 0.25mg semaglutide and gradually increase over months. The dramatic results from trials took over a year to achieve, not weeks.
The financial reality is absent too. These medications cost $800-1,200 monthly without insurance coverage. Many insurance plans don't cover them for weight loss, making this transformation financially out of reach for many viewers.
Is partnering with a telehealth company problematic?
Mercedes's #shedpartner hashtag reveals she has a financial relationship with the company she's promoting. That doesn't automatically invalidate her results, but it does create a clear conflict of interest that viewers should know about.
Telehealth platforms have made GLP-1 medications more accessible, which can be positive. But they've also been criticized by endocrinologists for sometimes inadequate monitoring and follow-up care compared to traditional medical settings.
The FDA has warned about compounded versions of these drugs sold by some telehealth companies. While we don't know what specific medication Mercedes used, buyers should verify they're getting FDA-approved versions from legitimate pharmacies.
What should viewers actually take away?
Mercedes's results appear consistent with what's possible on GLP-1 medications, based on clinical trial data. But her experience represents a best-case scenario, not a typical outcome.
Anyone considering these medications should discuss realistic expectations with a healthcare provider. The STEP trials showed that about 16% of people discontinued semaglutide due to side effects or other issues.
Success stories like Mercedes's can be motivating, but they shouldn't be the only factor in medical decision-making. The most honest takeaway? These drugs can work remarkably well for some people, but they're not magic solutions for everyone.